Arecor Therapeutics PLC Grant of Options and PDMR Dealing
02 12월 2024 - 4:00PM
RNS Regulatory News
RNS Number : 2650O
Arecor Therapeutics PLC
02 December 2024
Arecor Therapeutics plc
("Arecor" or "the Company")
Grant of Options and PDMR Dealing
Cambridge, UK, 2
December 2024: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable
healthier lives, announces that on 2nd December 2024 the
Company granted a total of 280,000 options under the Company's Long
Term Incentive Plan ("LTIP
Options") over new ordinary shares of 1 pence each in the
Company ("Ordinary
Shares").
The LTIP Options have an exercise price of 1 pence
and are granted to certain persons discharging managerial
responsibilities ("PDMRs")
of the Company. Performance conditions include commercial
objectives and Share Price Performance* during the three-year
performance period. The LTIP Options are subject to continued
service and the extent to which the performance conditions are
satisfied. Vested LTIP Options will normally be exercisable until
the tenth anniversary of the grant date, after which time they will
lapse. They are subject to a condition that the LTIP Options or the
Ordinary Shares acquired on exercise of the LTIP Options (other
than those sold to cover tax and National Insurance) are held for a
minimum one-year period from vesting.
*Outperformance
when compared to the FTSE AIM All Share index
The notifications below, made in accordance with the
requirements of the Market Abuse Regulation, provide further
detail.
-ENDS-
For more information,
please contact:
|
Arecor Therapeutics
plc
|
www.arecor.com
|
|
Dr Sarah Howell, Chief Executive Officer
|
Tel: +44 (0) 1223 426060
Email: info@arecor.com
|
|
|
|
|
Panmure Liberum
Limited (NOMAD and Joint Broker)
|
|
|
Emma Earl, Freddy Crossley, Mark Rogers (Corporate
Finance)
Rupert Dearden (Corporate Broking)
|
Tel: +44 (0) 20 7886 2500
|
|
WG Partners
LLP (Joint Broker)
|
|
|
Nigel Barnes, Satheesh Nadarajah
David Wilson, Claes Spang
|
Tel: +44 (0)203 705 9321
|
|
|
|
|
ICR
Healthcare
|
|
|
Chris Gardner, David Daley, Lindsey Neville
|
Tel: +44 (0) 20 3709 5700
Email: arecor@consilium-comms.com
|
|
|
|
Notes to
Editors
About
Arecor
Arecor Therapeutics plc is a globally focused
biopharmaceutical company transforming patient care by bringing
innovative medicines to market through the enhancement of existing
therapeutic products. By applying our innovative proprietary
technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other
indications, as well as working with leading pharmaceutical and
biotechnology companies to deliver therapeutic products. The
Arestat™ platform is supported by an extensive patent
portfolio.
For further details please see our website, www.arecor.com
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
|
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name:
|
1) Sarah
Howell
2) Jan Jezek
3) David Gerring
|
|
2.
|
Reason for the notification
|
|
a)
|
Position/status:
|
1) Chief Executive Officer and
Executive Director
2) PDMR (Chief Scientific
Officer)
3) PDMR (Chief Development
Officer)
|
|
b)
|
Initial
notification/Amendment:
|
Initial notification
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name:
|
Arecor Therapeutics plc
|
|
b)
|
LEI:
|
98450093D12I3A8DDD58
|
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument:
Identification code:
|
Ordinary shares of 1
pence each
|
|
b)
|
Nature of the
transaction:
|
Grant of options over ordinary
shares
|
|
c)
|
Price(s) and volume(s):
|
|
Exercise Price(s) (£)
|
Volume(s)
|
|
1)
£0.01
|
1) 160,000
|
|
2)
£0.01
|
2) 60,000
|
|
3)
£0.01
|
3) 60,000
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information:
· Aggregated volume:
· Price:
|
280,000
£0.01
|
|
e)
|
Date of the transaction:
|
2nd December 2024
|
|
f)
|
Place of the transaction:
|
Outside of a trading
venue
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHFLFVDLTLAFIS
Arecor Therapeutics (LSE:AREC)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Arecor Therapeutics (LSE:AREC)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
